Amphastar Pharmaceuticals(US:AMPH) Zacks Investment Researchยท2024-02-09 23:46Company Performance - Amphastar Pharmaceuticals (AMPH) closed at $55.61, with a daily increase of +1.85%, outperforming the S&P 500's gain of 0.57% [1] - Over the past month, AMPH shares gained 1.05%, lagging behind the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07% [1] - The upcoming EPS for Amphastar is projected at $0.87, indicating a 19.18% increase year-over-year, while revenue is estimated at $174.9 million, reflecting a 29.54% increase compared to the same quarter last year [1] Analyst Estimates - Recent changes to analyst estimates for Amphastar Pharmaceuticals reflect shifting business dynamics, with positive adjustments indicating a favorable outlook on the company's health and profitability [2] - The Zacks Rank system, which incorporates estimate changes, currently ranks Amphastar at 3 (Hold), with the consensus EPS estimate remaining unchanged over the last 30 days [2] Valuation Metrics - Amphastar Pharmaceuticals has a Forward P/E ratio of 14.47, which aligns with the industry's Forward P/E of 14.47 [3] - The company has a PEG ratio of 0.64, compared to the Medical - Generic Drugs industry's average PEG ratio of 1.33 [3] - The Medical - Generic Drugs industry holds a Zacks Industry Rank of 169, placing it in the bottom 33% of over 250 industries [3]